A Tumor-Localized Approach to Bypass Anti-4-1BB Immuno-Toxicity
暂无分享,去创建一个
[1] L. Matis,et al. Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343 , 2019, Clinical Cancer Research.
[2] J. Zapata,et al. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity , 2018, Nature Communications.
[3] I. Melero,et al. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. , 2018, Blood.
[4] Lieping Chen,et al. S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity , 2017, Oncoimmunology.
[5] Lieping Chen,et al. This information is current as Hepatitis B Virus-Transgenic Mice Hepatitis to Hepatocellular Carcinoma in CD 137-Mediated Pathogenesis from Chronic , 2010 .